- Home
- PAVS vs MDXH Comparison
PAVS vs MDXH Comparison
Compare PAVS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAVS | MDXH |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 167.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAVS | MDXH |
|---|---|---|
| Price | $2.20 | $3.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 5.5M | 119.9K |
| Earning Date | 08-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,416,127.00 | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18037.91 | 21.68 |
| 52 Week Low | $1.38 | $1.35 |
| 52 Week High | $150.00 | $5.33 |
Technical Indicators
Market Signals| Indicator | PAVS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 46.11 |
| Support Level | $1.38 | $3.11 |
| Resistance Level | $3.83 | $3.58 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | 0.20 | 0.04 |
| Stochastic Oscillator | 55.16 | 59.46 |
Price Performance
Historical ComparisonAbout PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.